• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.泪腺腺样囊性癌的预后因素:一项针对中国患者的回顾性研究。
Int J Ophthalmol. 2024 Aug 18;17(8):1423-1430. doi: 10.18240/ijo.2024.08.06. eCollection 2024.
2
Clinical and histopathological factors for recurrence and metastasis in lacrimal gland adenoid cystic carcinoma in Chinese patients.中国患者泪腺腺样囊性癌复发和转移的临床及组织病理学因素
Eur J Ophthalmol. 2025 Jan;35(1):375-382. doi: 10.1177/11206721241249503. Epub 2024 Apr 30.
3
Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma.新辅助动脉内细胞减灭化疗改善泪腺腺样囊性癌的预后。
Oncologist. 2024 Mar 4;29(3):263-269. doi: 10.1093/oncolo/oyad346.
4
Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma.泪腺癌局部复发和生存的预后因素以及局部治疗对生存的影响。
Br J Ophthalmol. 2021 Jun;105(6):768-774. doi: 10.1136/bjophthalmol-2020-316142. Epub 2020 Jul 17.
5
Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy.新辅助动脉内细胞减灭化疗治疗泪腺腺样囊性癌:三联治疗策略的长期随访研究。
Am J Ophthalmol. 2022 Aug;240:239-251. doi: 10.1016/j.ajo.2022.03.027. Epub 2022 Apr 2.
6
Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma.泪腺腺样囊性癌治疗中的多模态疗法
BMC Ophthalmol. 2019 Jun 8;19(1):125. doi: 10.1186/s12886-019-1110-5.
7
Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland.泪腺腺样囊性癌保留眼球手术的长期预后
Ophthalmic Plast Reconstr Surg. 2018 Jan/Feb;34(1):74-78. doi: 10.1097/IOP.0000000000000877.
8
Recurrent lacrimal gland adenoid cystic carcinoma: A case report and literature review.复发性泪腺腺样囊性癌:一例报告及文献复习
Heliyon. 2024 Jun 28;10(14):e33889. doi: 10.1016/j.heliyon.2024.e33889. eCollection 2024 Jul 30.
9
Spatial Transcriptomics Identifies Expression Signatures Specific to Lacrimal Gland Adenoid Cystic Carcinoma Cells.空间转录组学鉴定泪腺腺样囊性癌细胞特异性表达特征。
Cancers (Basel). 2023 Jun 16;15(12):3211. doi: 10.3390/cancers15123211.
10
Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database.眼眶腺样囊性癌与腺癌的临床特征及预后差异:来自监测、流行病学和最终结果(SEER)18数据库的研究
Tumori. 2023 Feb;109(1):61-70. doi: 10.1177/03008916211070328. Epub 2022 Feb 3.

本文引用的文献

1
Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis.泪腺腺样囊性癌的治疗:一项系统评价和Meta分析。
Int J Ophthalmol. 2024 Jan 18;17(1):164-172. doi: 10.18240/ijo.2024.01.22. eCollection 2024.
2
Apoptotic Marker Expression of Resected Lacrimal Gland Adenoid Cystic Carcinoma Tumor Margins After Intra-arterial Chemotherapy and Globe-Sparing Excision.经动脉化疗和保眼球切除术切除后泪腺腺样囊性癌肿瘤边缘的凋亡标志物表达。
Ophthalmic Plast Reconstr Surg. 2024;40(2):206-211. doi: 10.1097/IOP.0000000000002548. Epub 2023 Nov 16.
3
A Review of the Molecular Landscape of Adenoid Cystic Carcinoma of the Lacrimal Gland.泪腺腺样囊性癌的分子景观研究综述。
Int J Mol Sci. 2023 Sep 6;24(18):13755. doi: 10.3390/ijms241813755.
4
Spatial Transcriptomics Identifies Expression Signatures Specific to Lacrimal Gland Adenoid Cystic Carcinoma Cells.空间转录组学鉴定泪腺腺样囊性癌细胞特异性表达特征。
Cancers (Basel). 2023 Jun 16;15(12):3211. doi: 10.3390/cancers15123211.
5
Preliminary proteomic analysis of human tears in lacrimal adenoid cystic carcinoma and pleomorphic adenoma.泪腺腺样囊性癌和多形性腺瘤患者泪液的初步蛋白质组学分析。
Int J Ophthalmol. 2023 Jun 18;16(6):841-848. doi: 10.18240/ijo.2023.06.02. eCollection 2023.
6
Comparison of biological behavior of lacrimal gland adenoid cystic carcinoma with high-grade transformation cells.泪腺腺样囊性癌伴高级别转化细胞的生物学行为比较
Int J Ophthalmol. 2023 Feb 18;16(2):163-171. doi: 10.18240/ijo.2023.02.01. eCollection 2023.
7
Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor.涎腺和泪腺及乳腺腺样囊性癌:同一肿瘤不同的临床结局。
Crit Rev Oncol Hematol. 2022 Nov;179:103792. doi: 10.1016/j.critrevonc.2022.103792. Epub 2022 Aug 13.
8
Clinical and radiologic outcomes of pleomorphic adenoma and adenoid cystic carcinoma of the lacrimal gland.泪腺多形性腺瘤和腺样囊性癌的临床及影像学结果
Arq Bras Oftalmol. 2023 Jul-Aug;86(4):359-364. doi: 10.5935/0004-2749.20230056.
9
Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.贝伐单抗是一种对泪腺腺样囊性癌患者来源异种移植瘤具有低副作用的有效治疗方法。
Cancer Manag Res. 2022 Mar 6;14:1023-1032. doi: 10.2147/CMAR.S352623. eCollection 2022.
10
Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database.眼眶腺样囊性癌与腺癌的临床特征及预后差异:来自监测、流行病学和最终结果(SEER)18数据库的研究
Tumori. 2023 Feb;109(1):61-70. doi: 10.1177/03008916211070328. Epub 2022 Feb 3.

泪腺腺样囊性癌的预后因素:一项针对中国患者的回顾性研究。

Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.

作者信息

Yang Lu-Di, Jia Shi-Chong, Yang Jie, Song Xin, Wang Ye-Fei, Fan Xian-Qun

机构信息

Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.

Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China.

出版信息

Int J Ophthalmol. 2024 Aug 18;17(8):1423-1430. doi: 10.18240/ijo.2024.08.06. eCollection 2024.

DOI:10.18240/ijo.2024.08.06
PMID:39156780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11286454/
Abstract

AIM

To explore the prognostic factors for lacrimal gland adenoid cystic carcinoma (LGACC) in Chinese patients.

METHODS

Clinical and histopathological data were reviewed in patients with pathologically confirmed LGACC. Local recurrence, metastasis, and disease-specific death were the main outcome measures. Univariate and multivariate analyses were performed by the Kaplan-Meier method and a Cox proportional hazard model.

RESULTS

This retrospective cohort study included 45 patients with pathologically confirmed LGACC between January 2008 and June 2022. Tumor (T) classification (=0.005), nodal metastasis (N) classification (=0.018) and positive margin (=0.008) were independent risk factors of recurrence; T (=0.013) and N (=0.003) classification and the basaloid tumor type (=0.032) were independent risk factors for metastasis; T classification (<0.001) was an independent factor of death of disease. In the further analysis, the durations from first surgery to radiotherapy is correlated with metastatic risk in LGACC patients with basaloid component (=0.022).

CONCLUSION

Histological subtype should be emphasized when evaluating prognosis and guiding treatment. Timely radiotherapy may reduce the risk of metastasis in patients with basaloid component.

摘要

目的

探讨中国泪腺腺样囊性癌(LGACC)患者的预后因素。

方法

回顾经病理确诊的LGACC患者的临床和组织病理学资料。局部复发、转移和疾病特异性死亡为主要观察指标。采用Kaplan-Meier法和Cox比例风险模型进行单因素和多因素分析。

结果

这项回顾性队列研究纳入了2008年1月至2022年6月期间45例经病理确诊的LGACC患者。肿瘤(T)分级(=0.005)、淋巴结转移(N)分级(=0.018)和切缘阳性(=0.008)是复发的独立危险因素;T分级(=0.013)、N分级(=0.003)和基底样肿瘤类型(=0.032)是转移的独立危险因素;T分级(<0.001)是疾病死亡的独立因素。在进一步分析中,首次手术至放疗的时间与具有基底样成分的LGACC患者的转移风险相关(=0.022)。

结论

在评估预后和指导治疗时应强调组织学亚型。及时放疗可能降低具有基底样成分患者的转移风险。